Is Retatrutide FDA Approved? When It May Be Available

No. As of November 2026, retatrutide is not approved by the FDA or by any other regulator in the world. Eli Lilly, the company developing it, plans to submit it to the FDA in the first quarter of 2027. Under the FDA's review goals, a decision on a new biologic usually comes about 8 to 12 months after the company files, so the earliest realistic approval is late 2027, and 2028 is more likely under a standard review. Until then, retatrutide has no legal price, cannot be compounded, and can be used legally only in clinical trials or Lilly's expanded access program.

MaxLife does not offer retatrutide. If you want treatment now, tirzepatide, the medicine in Zepbound® and Mounjaro®, has been FDA-approved since 2022 and can be prescribed today. Compounded tirzepatide costs $120/mo flat at MaxLife, the same price at every dose. It is not FDA-approved, and a licensed provider decides whether it is right for you.

Retatrutide Status at a Glance (November 2026)

Sources: Lilly's retatrutide FAQ (updated October 2026), Lilly's July 23, 2026 release, the FDA and ClinicalTrials.gov, checked November 2026.

Is Retatrutide FDA Approved?

No. Retatrutide is an investigational drug, which means it is still being tested in clinical trials and has not been approved for sale. Lilly's own FAQ says retatrutide "has not been reviewed or approved by the FDA or any regulatory agency in the world, and no one can legally sell it for human use." In its October 28, 2026 release, Lilly added that "anyone purporting to sell retatrutide to consumers is breaking the law."

Retatrutide has done well in its late-stage trials. In TRIUMPH-1, published in The New England Journal of Medicine in November 2026, adults without diabetes on the highest dose tested lost an average of 25.0% of their body weight over 80 weeks, compared with 3.9% on placebo. Lilly says its trial results now support filing for three uses: obesity, knee osteoarthritis pain and obstructive sleep apnea. Strong trial results are not an approval, though. The FDA still has to review the full application, including how the drug is made. For every trial result and the side effects, see our comparison of retatrutide vs tirzepatide.

Has Lilly Submitted Retatrutide to the FDA Yet?

Not as of November 2026. On July 23, 2026, Lilly said it was completing the manufacturing data package (called CMC, for chemistry, manufacturing and controls) that a Biologics License Application requires, and that it plans to submit retatrutide in the first quarter of 2027. Lilly's third-quarter results on October 29, 2026 listed retatrutide only under clinical news, and its November 5, 2026 release still calls it "an investigational molecule that cannot be legally sold or marketed for human use." Lilly's medical information page adds that "there is no guarantee that it will receive regulatory approval or that any anticipated submission timeline will be met."

When Will Retatrutide Be Available?

There is no approval date yet. Lilly's answer is that "launch will depend on the completion of these trials and the regulatory approval process." What you can estimate is how long each step usually takes once Lilly files:

The review clock comes from the FDA's user fee commitment letter: for a new biologic, the clock starts after a 60-day filing review, and the FDA aims to act within 6 months under priority review or 10 months under standard review. If Lilly files in early 2027, a decision would most likely come between late 2027 and early 2028. That is our estimate from the FDA's published goals, not a date from Lilly or the FDA.

What Could Speed Up or Slow Down Approval?

Several things could move the timeline:

• A national priority voucher. The FDA's voucher pilot program targets decisions in 1 to 2 months. Lilly's Foundayo pill used one and was approved on April 1, 2026, 50 days after filing. As of November 2026, neither Lilly nor the FDA has announced a voucher for retatrutide.
• The head-to-head trial. TRIUMPH-5 compares retatrutide with tirzepatide in about 800 adults. ClinicalTrials.gov lists its primary completion, when the main data are collected, as estimated for November 2026. No results have been announced.
• FDA questions. A request for more data, an advisory committee meeting or a manufacturing issue can add months to any review.

How Much Does Retatrutide Cost per Month?

Retatrutide has no legal price, because it is not on the market. Lilly says that after the trials and the FDA review, "we plan to ensure retatrutide is priced to reflect the overall value to the healthcare system." It has not announced a number.

That means any "retatrutide price per month" you see online is the price of an illegal product, not a medicine. Some search answers even list "compounded retatrutide" prices. That route does not exist legally: the FDA says retatrutide cannot be compounded (see below). Monthly price guesses for after approval also come from analysts, not from Lilly.

Will Insurance Cover Retatrutide?

No. Insurance plans and Medicare cover FDA-approved drugs, and retatrutide isn't one. The Medicare GLP-1 Bridge, which since July 1, 2026 lets eligible Part D members get some weight-loss drugs for a $50 copay, covers approved medicines such as Foundayo, Wegovy® and the Zepbound KwikPen, not retatrutide. Coverage after approval will depend on each plan.

Can You Get Retatrutide Legally Right Now?

Only through research. In the U.S., there are two legal ways to receive retatrutide today:

1. A clinical trial. Most of Lilly's TRIUMPH obesity trials have finished enrolling. As of November 2026, ClinicalTrials.gov lists one Lilly retatrutide study that is still recruiting: SYNERGY-OUTCOMES, a study of adults with a liver disease called MASLD, in which participants may receive retatrutide, tirzepatide or placebo. Trial staff decide who qualifies.
2. Expanded access. Lilly's medical information page describes a narrow program for people who cannot join a trial and "have exhausted all available medical options."

The criteria are strict, and the request has to come from your own physician, who applies to the FDA for a single-patient investigational new drug application. Lilly provides the drug at no cost, does not ship it to patients, and ends the program after approval. Lilly's page lists the full criteria.

Is Compounded Retatrutide Legal?

No. The FDA states: "Retatrutide and cagrilintide cannot be used in compounding under federal law. Additionally, these are not components of FDA-approved drugs and have not been found safe and effective for any condition." The FDA also says it has warned telehealth companies for marketing unapproved drugs such as retatrutide directly to consumers, and outsourcing facilities for repackaging it (FDA, content current October 2026). If a clinic, med spa or website offers retatrutide, it is not a legal prescription.

What About "Research Peptide" Retatrutide?

Vials sold online as "research use only" or "not for human consumption" are not a legal or safe way to get retatrutide. The FDA has warned companies that sold such products containing retatrutide and other GLP-1 drugs "directly to consumers for human use with dosing instructions," and urges people not to buy them because they "are of unknown quality and may be harmful to their health." Lilly warns that illicit retatrutide "may contain unknown ingredients, harmful contaminants and impurities," or too much, too little or the wrong ingredient. In August 2026, Lilly said it had reported more than 14,000 websites, ads, posts and listings illegally marketing retatrutide.

Our guide to what a "research peptide" label really means explains the risks, and our overview of peptides for weight loss shows which ones are FDA-approved and which are not.

What Is GLP-3, and Is Retatrutide a GLP-1?

"GLP-3" is a nickname, not a hormone or a drug class. Lilly calls it "a scientifically inaccurate label used informally in the media" and prefers "triple agonist." People started calling retatrutide a GLP-3 because one molecule acts on three hormone receptors: GIP, GLP-1 and glucagon. Online, you may also see it called "reta" or "GLP-3 RT," often on illegal "research" listings.

So is retatrutide a GLP-1? Partly. It activates the GLP-1 receptor, plus two others. For comparison:

• Semaglutide (Ozempic®, Wegovy) acts on one receptor, GLP-1.
• Tirzepatide (Zepbound, Mounjaro) acts on two, GIP and GLP-1.
• Foundayo (orforglipron) is a daily pill that acts on GLP-1 only.
• Retatrutide acts on three: GIP, GLP-1 and glucagon. Glucagon mainly acts on the liver and may raise the energy the body burns.

What Can You Take Now Instead of Retatrutide?

You have several FDA-approved options today, plus lower-cost compounded versions of two of them:

Prices from LillyDirect, LillyDirect Foundayo and NovoCare, checked November 2026. LillyDirect's top Zepbound price needs a refill within 45 days, and Foundayo's lower prices on two doses run through December 31, 2026.

Some routes are better for some people. If your insurance covers a brand, it may cost you less than any cash option. Zepbound is the tirzepatide brand approved for sleep apnea, and Mounjaro is the one approved for type 2 diabetes. If you don't want injections, ask about a pill; our guide to the tirzepatide pill question and Foundayo explains the options. For every legal route to tirzepatide, see how to get tirzepatide, and for prices by route, our tirzepatide cost guide.

Should You Wait for Retatrutide or Start Treatment Now?

That's a decision for you and your provider, but here is what the dates mean. Even on the fastest normal path, retatrutide is unlikely to reach pharmacies before late 2027, and no one can promise when. Tirzepatide is available now, and its evidence is deep: in the SURMOUNT-1 trial, adults on Zepbound lost an average of 15.0% to 20.9% of their body weight over 72 weeks, compared with 3.1% on placebo (Zepbound label), and in a 3-year follow-up of adults with prediabetes, weight loss averaged 12.3% to 19.7% at 176 weeks, compared with 1.3% on placebo. These results belong to Zepbound; they have not been shown for compounded tirzepatide.

If retatrutide is approved later, you can talk with your provider about it then. Don't plan to take it alongside another GLP-1 medicine: the Zepbound label says tirzepatide should not be used with any other GLP-1 receptor agonist, and no official conversion between the two exists.

Compounded tirzepatide is the lower-cost cash route to tirzepatide. Compounded tirzepatide is prepared by a licensed pharmacy for one patient's prescription and is not FDA-approved, which means the FDA hasn't reviewed it for safety, effectiveness or quality. It is not Zepbound or Mounjaro.

Here is how MaxLife works. MaxLife is a telehealth patient management platform, not a pharmacy or drug maker, and it does not offer retatrutide. You complete an online intake in about 2 minutes. A licensed provider reviews your online intake, health history and clinical records, usually within 24 hours, can follow up with questions, and you can ask for a video visit. If the provider decides compounded tirzepatide is right for you, licensed partner pharmacies prepare and dispense it. The price is $120/mo flat, the same price at every dose, and it includes the provider's review and follow-up, the medicine if prescribed, supplies and free expedited shipping, with no membership fee. No insurance is needed, HSA and FSA funds may be eligible, and MaxLife serves all 50 states. See whether you qualify on the compounded tirzepatide page, or read about compounded semaglutide, $89/mo flat, which is also not FDA-approved.

The Bottom Line

Retatrutide is not FDA-approved as of November 2026, and it is not approved anywhere else. Lilly plans to file in the first quarter of 2027, which puts the earliest likely FDA decision in late 2027, with 2028 more likely under a standard review. It has no legal price, it cannot be compounded, and the only legal access is a clinical trial or Lilly's narrow expanded access program. Anything sold online as retatrutide today is illegal. If you want treatment now, ask a licensed provider about an approved option such as Zepbound or about compounded tirzepatide, which is not FDA-approved.